Although we observed differential AXDND1 expression in oxaliplatin-resistant CRC samples and a correlation with patient prognosis, functional assays indicated limited effects on oxaliplatin sensitivity, suggesting its role as a passive biomarker. The gene discussed is AXDND1; the disease is colorectal carcinoma.